Loading organizations...
§ Private Profile · Princeton, NJ, USA
QuantX Biosciences is a biotechnology company that specializes in computational drug discovery and small-molecule therapeutic products.
QuantX Biosciences is a biotechnology company established in 2022 and headquartered in Princeton, New Jersey. The company specializes in modern computation-powered drug discovery, focusing on the development of small-molecule therapeutic products.
Its core mission involves identifying and advancing oral small molecule therapeutics, with a particular emphasis on immunology and inflammatory targets. This strategic focus leverages advanced computational methods to address unmet medical needs within these specific therapeutic areas, aiming to bring forward novel treatment options.
QuantX Biosciences has raised $85.0M across 1 funding round.
QuantX Biosciences was founded in 2022 and is headquartered in Princeton, New Jersey, USA.
QuantX Biosciences has raised $85.0M across 1 funding round. Most recently, it raised $85.0M Series B in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 9, 2026 | $85M Series B | Lilly Asia Ventures, Sanofi Ventures | Hongshan Capital Group (Sequoia Capital China) | Announced |
QuantX Biosciences is a biotechnology company founded in 2022 and based in Princeton, New Jersey. The organization operates within the pharmaceutical sector, concentrating its efforts on the discovery and development of novel therapeutic solutions. As a private entity, QuantX Biosciences is engaged in advancing its pipeline of drug candidates.
The company's primary specialization lies in computational drug discovery. QuantX Biosciences leverages modern computation-powered approaches to identify and develop small-molecule therapeutic products. This methodology is central to its strategy for efficiently exploring chemical spaces and predicting potential drug candidates.
QuantX Biosciences specifically targets the development of oral small molecule therapeutics. Its research and development initiatives are focused on addressing conditions within immunology and inflammatory targets. This strategic therapeutic area selection reflects an aim to contribute to treatments for diseases where there is a significant need for new medical interventions.
While specific details of its internal operations and product pipeline are not publicly detailed, the company's official website features dedicated sections for its 'Team,' 'Technology,' and 'Pipeline.' These sections indicate a structured approach to its scientific and corporate development. QuantX Biosciences maintains a presence on professional networking platforms, where it identifies its industry as biotechnology and reports a company size of 11-50 employees.